Table 2 Summary of clinico-pathological variables in epithelial ovarian cancer patients (n = 127).
From: PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients
n (%) | |
|---|---|
Age | |
Mean ± SD | 39.7 ± 9.8 |
Median (range) | 41.3 (17–66) |
≤ 30 | 30 (23.6) |
31–40 | 29 (22.8) |
41—50 | 59 (46.5) |
51–60 | 8 (6.3) |
> 60 | 1 (0.8) |
Family history of cancer | |
No | 118 (92.9) |
Yes | 9 (7.1) |
Histopathology | |
High grade serous | 56 (44.1) |
Low grade serous | 27 (21.3) |
Mucinous | 20 (15.7) |
Endometrioid | 16 (12.6) |
Clear cell | 3 (2.4) |
Undifferentiated | 5 (3.9) |
Histological grade | |
Grade 1 | 33 (26.0) |
Grade 2 | 53 (41.7) |
Grade 3 | 40 (31.5) |
Unknown | 1 (0.8) |
pT | |
T1 | 29 (22.8) |
T2 | 13 (10.2) |
T3 | 85 (67.0) |
pN | |
N0 | 120 (94.5) |
N1 | 7 (5.5) |
pM | |
M0 | 105 (82.7) |
M1 | 22 (17.3) |
Stage | |
I | 29 (22.8) |
II | 9 (7.1) |
III | 67 (52.8) |
IV | 22 (17.3) |
